At 10 years, treatment with leuprorelin did not significantly improve OS (89.1% vs 88.9%) or disease-specific survival (98.6% vs 96.5%) compared with observation. The administration of leuprorelin ...
Evaluation of the safety and efficacy of daily oral Angelica gigas Nakai (AGN)-INM176 in prostate cancer patients with rising plasma PSA (phase I/II trial). This is an ASCO Meeting Abstract from the ...
Hypofractionated radiotherapy for prostate cancer (HYDRA): An individual patient data meta-analysis of randomized trials in the MARCAP consortium. Androgen suppression with abiraterone acetate, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results